HIV trispecific antibody - OPKO Health
Latest Information Update: 05 Mar 2024
At a glance
- Originator ModeX Therapeutics Inc
- Developer National Institutes of Health; OPKO Health
- Class Antiretrovirals; Trispecific antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HIV infections
Most Recent Events
- 17 Jan 2024 ModeX Therapeutics Inc has been acquired by OPKO Health
- 21 Mar 2023 Phase-I clinical trials in HIV infections (Parenteral) prior to March 2023 (ModeX Therapeutics pipeline, March 2023)
- 21 Mar 2023 Phase-I clinical trials in HIV infections (Prevention) (Parenteral) prior to March 2023 (ModeX Therapeutics pipeline, March 2023)